There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oncolytics Biotech (ONCY – Research Report) and Precigen (PGEN – Research Report) with bullish sentiments.
Oncolytics Biotech (ONCY)
Maxim Group analyst Jason McCarthy maintained a Buy rating on Oncolytics Biotech yesterday and set a price target of $3.00. The company’s shares closed last Wednesday at $1.64.
According to TipRanks.com, McCarthy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Oncolytics Biotech with a $6.84 average price target, implying a 319.6% upside from current levels. In a report issued on May 5, RBC Capital also maintained a Buy rating on the stock with a C$6.00 price target.
See the top stocks recommended by analysts >>
Precigen (PGEN)
In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Precigen, with a price target of $14.00. The company’s shares closed last Wednesday at $1.21.
According to TipRanks.com, Butler has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Precigen is a Strong Buy with an average price target of $8.77.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ONCY:
